Raloxifene does not prevent fibrinogen oxidation in vitro

Medical Science Monitor

Volumn 11, Issue 1, 2005, Pages

  Blasbichler, Margit ^a   Arakil Aghajanian, Arsineh ^a   Sinzinger, Helmut ^a,b  

^a ATHOS   (Austria)

^b Wilhelm Auerswald Atherosclerosis Research Group   (Austria)

Author keywords

Atherosclerosis; Fibrinogen; Hormone replacement therapy; Oxidation; Raloxifene (LY 139481); Thrombosis

Indexed keywords

FIBRINOGEN; GLYCOPROTEIN; LOW DENSITY LIPOPROTEIN; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ARTICLE; ATHEROSCLEROSIS; CONCENTRATION RESPONSE; DRUG EFFECT; HORMONE SUBSTITUTION; IN VITRO STUDY; INCUBATION TIME; LIPOPHILICITY; OXIDATION; PATHOPHYSIOLOGY; POSTMENOPAUSE; PROTEIN MODIFICATION; PROTEIN STRUCTURE; THROMBOSIS;

ANTIOXIDANTS; FIBRINOGEN; IRON; OXIDATION-REDUCTION; RALOXIFENE;

EID: 12244265496     PISSN: 12341010     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Gensini GF, Micheli S, Frisco D, Abbate R: Menopause and risk of cardiovascular disease. Thromb Res, 1996; 18: 1-18
2. Pacifici RE, Davies KJA: Protein degradation as an index of oxidative stress. Meth Enzymol, 1990; 186: 485-502
3. Wilhelmsen L, Svardsudd K, Korsan-Bengtsen K et al: Fibrinogen as a risk factor for stroke and myocardial infarction. New Engl J Med, 1984; 311: 501-5
4. Kannel W, Wolf P, Castelli W, D'Agostino R: Fibrinogen and risk of cardiovascular disease. The Framingham Sutdy. JAMA, 1987; 258: 1183-86
5. Shacter E, Williams JA, Levine RL: Oxidative modification of fibrinogen inhibits thrombin-catalyzed clot formation. Free Rad Biol Med, 1995; 18: 815-21
6. Shats EA, Nair CH, Dhall DP: Interaction of endothelial cells and fibroblasts with modified fibrin networks: role in atherosclerosis. Atherosclerosis, 1997; 129: 9-15
7. Grese TA, Pennington LD, Sluka JP et al: Synthesis and pharmacology of conformationally restricted raloxifene analogues: highly potent selective estrogen receptor modulators. J Med Chem, 1998; 41: 1272-83
8. Zuckerman SH, Bryan N: Inhibition of LDL-oxidation and myeloperoxidase-dependent tyrosyl radical formation by the selective estrogen receptor modulator raloxifene (LY 139481 HCL). Atherosclerosis. 1996; 126: 64-75
9. Lee Y, Shacter E: Role of carbohydrates in oxidative modification of fibrinogen and other plasma proteins. Arch Biochem Biophys, 1995; 321: 175-81
10. Levine RL, Williams JA, Stadtman ER, Shacter E: Carbonyl assays for determination of oxidatively modified proteins. Meth Enzymol, 1994; 233: 346-57
11. Levine RL, Garland D, Oliver CN et al: Determination of carbonyl content in oxidatively modified proteins. Meth Enzymol, 1990; 186: 486-78
12. Kauffman RF, Bensch WR, Roudebush RE et al: Hypocholesterolemic activity of raloxifene (LY139481): Pharmacological characterization as a selective estrogen receptor modulator. J Pharm Exp Ther, 1997; 297: 1445-51
13. Walsh BW, Kuller LH, Wild RA et al: Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA, 1998; 297: 1445-51
14. Delmas PD, Mjarnson NH, Bruce MD et al: Effects of raloxifene on bone mineral density, serum cholesterol, and uterine endometrium in postmenopausal women. N Engl J Med, 1997; 337: 1641-47
15. Rattan K, Arad Y: Inhibition of LDL-oxidation by a new estradiol receptor modulator compound LY-139478, comparative effect with other steroids. Atherosclerosis, 1998; 136: 305-14
16. Meade TW, Chakrabarti R, Haines AP et al: Haemostatic function and cardiovascular death: early results of a prospective study. Lancet, 1980; 17: 1050-53